METHODS: A total of 102 patients were randomized to either mono-therapy with simvastatin (40 mg daily) or triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. RESULTS: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity (p = 0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy (p = 0.01). CONCLUSION: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. CLINICAL TRIAL REGISTRATION INFORMATION: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/NCT00687076.
RCT Entities:
METHODS: A total of 102 patients were randomized to either mono-therapy with simvastatin (40 mg daily) or triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. RESULTS: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity (p = 0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy (p = 0.01). CONCLUSION: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. CLINICAL TRIAL REGISTRATION INFORMATION: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/NCT00687076.
Authors: Alan T Hirsch; Timothy P Murphy; Marge B Lovell; Gwen Twillman; Diane Treat-Jacobson; Eileen M Harwood; Emile R Mohler; Mark A Creager; Robert W Hobson; Rose Marie Robertson; W James Howard; Paul Schroeder; Michael H Criqui Journal: Circulation Date: 2007-09-17 Impact factor: 29.690
Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245
Authors: Mary M McDermott; Kiang Liu; Jack M Guralnik; Michael H Criqui; Bonnie Spring; Lu Tian; Kathryn Domanchuk; Luigi Ferrucci; Donald Lloyd-Jones; Melina Kibbe; Huimin Tao; Lihui Zhao; Yihua Liao; W Jack Rejeski Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Alan B Lumsden; Terry W Rice; Changyi Chen; Wei Zhou; Peter H Lin; Paul Bray; Joel Morrisett; Vijay Nambi; Christie Ballantyne Journal: World J Surg Date: 2007-04 Impact factor: 3.352
Authors: Gerd Brunner; Jean Bismuth; Vijay Nambi; Christie M Ballantyne; Addison A Taylor; Alan B Lumsden; Joel D Morrisett; Dipan J Shah Journal: Med Biol Eng Comput Date: 2016-02-23 Impact factor: 2.602
Authors: Hassan Kamran; Vijay Nambi; Smita Negi; Eric Y Yang; Changyi Chen; Salim S Virani; Panos Kougias; Alan B Lumsden; Joel D Morrisett; Christie M Ballantyne; Gerd Brunner Journal: Am J Cardiol Date: 2016-08-13 Impact factor: 2.778
Authors: Jaykrishna Singh; Gerd Brunner; Joel D Morrisett; Christie M Ballantyne; Alan B Lumsden; Dipan J Shah; Paolo Decuzzi Journal: Comput Methods Biomech Biomed Eng Imaging Vis Date: 2016-10-12